Agios Pharmaceuticals, Inc. (0HB0.L)
| Previous close | 49.15 |
| Open | 49.16 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 47.90 - 49.16 |
| 52-week range | 20.13 - 49.16 |
| Volume | |
| Avg. volume | 522 |
| Market cap | 2.178B |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.43 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksAgios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simply Wall St.Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Has Found A Path To Profitability
We feel now is a pretty good time to analyse Agios Pharmaceuticals, Inc.'s ( NASDAQ:AGIO ) business as it appears the...
GlobeNewswireAgios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, August 1, 2024, at 8:00 a.m. ET to report its second quarter 2024 financial results and other business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the
